Press Releases

NS Pharma announced today the opening of a new office in Cambridge, Massachusetts, to establish the NS Pharma Innovation Research Partnering division.The new Boston area location is the company's center for research and development in the United States and will diversify Nippon Shinyaku's R&D portfolio through open innovation. Cambridge, MA, is home to many notable universities, hospitals, research institutions, and bio-venture firms. Establishing a presence in this thriving drug

ViewRay, Inc.announced today that Chindex Medical Limited through its subsidiary, has ordered 10 MRIdian MR-Guided Therapy Systems. Chindex, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has been ViewRay's distribution partner since 2019. MRIdian received regulatory approval in September 2022 from the National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China. This approval expands MRIdian's global reach and offers cancer

Lantern Pharma Inc. a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration  has granted LP-284 Orphan Drug Designation for the treatment of mantle cell lymphoma. MCL is a rare and aggressive form of B-cell non-Hodgkin's lymphoma that is typically diagnosed at advanced stage

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical needs, today announced that, following a consultation with the U.S. Food and Drug Administration (“FDA”), Inventiva has decided to modify the clinical development plan of lanifibranor for the

Zhongchao Inc., a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang Pharmaceutical"), one of the Chinese operating entities of which the Company consolidates the financial results with through certain contractual arrangements, will act as the drug distribution agent of certain drugs produced by Natco Pharma Limited ("Natco") within Main

Blacksmith Medicines, Inc., and Forge Therapeutics, announce today that the companies have signed a definitive merger agreement to leverage their combined chemistry platforms, creating a leading biopharma dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes, with initial focus on oncology and infection. "We are excited to unveil the merger of Blacksmith and Forge, which we believe will be transformational for both companies

leon-nanodrugs GmbH, a disrupting enabler of nanotechnology for the pharmaceutical industry, today announces the successful completion of its reactor development. With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features. This is a technological breakthrough for production of LNPs, as well as for encapsulation of transfection material (such as mRNA) or active pharmaceutical ingredients (APIs), at

Biocytogen Pharmaceuticals Co., Ltd.a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMice Platforms and Hansoh Pharmaceutical Group Company Limited a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license a

Legend Biotech Corporation mercializing novel therapies to treat life-threatening diseases, announced today that China’s National Medical Products Administration has formally accepted its New Drug Application  for ciltacabtagene autoleucel. This submission is based on data from the confirmatory Phase 2 clinical study CARTIFAN-1 (NCT03758417) conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or refractory multiple myel

Reiterating its commitment to Make in India, Gufic Biosciences Limited (“Gufic”) a fast-growing pharmaceutical player recognized for its innovative, high-quality pharmaceutical and herbal products has launched indigenously produced ‘Zarbot’ (Botulinum Toxin Type A) injection in India. ‘Zarbot’ was unveiled by  Dr. Dirk Dressler, Dr. Balaram Singh and several other prominent Healthcare Practitioners of India in a well-attended event held in Mu